Managing oral anticoagulant therapy

Chest

Volumn 119, Issue 1 SUPPL., 2001, Pages 22S-38S

  Ansell, J ^a   Hirsh, J ^a   Dalen, J ^a   Bussey, H ^a   Anderson, D ^a   Poller, L ^a   Jacobson, A ^a   Deykin, D ^a   Matchar, D ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP; WARFARIN;

ANEMIA; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLEEDING; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; EMBRYOPATHY; FETUS DEATH; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAINTENANCE THERAPY; PATIENT MONITORING; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SKIN NECROSIS; THROMBOEMBOLISM;

EID: 0035125403     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.22S     Document Type: Conference Paper

References (168)

1. Atrial fibrillation and stroke: Three new studies, three remaining questions
2. Fifth ACCP Consensus Conference on Antithrombotic Therapy
3. The international normalized ratio: A guide to understanding and correcting its problems
4. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
5. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement
6. Trial of different intensities of anticoagulation in patients with prosthetic heart valves
7. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves
8. Risk factors for intracranial hemorrhage in outpatients taking warfarin
9. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
10. The optimal intensity of oral anticoagulant therapy in patients with mechanical heart valve prostheses: The Leiden artificial valve and anticoagulation study
11. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia
12. Risk factors for complications of chronic anticoagulation: A multicenter study
13. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
14. Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remedial lesions
15. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range
16. Calibration of reference thromboplastins and standardization of the prothrombin time ratio
17. Anticoagulation management as a risk factor for adverse events: Grounds for improvement
18. Quality of anticoagulation management among patients with atrial fibrillation: Results from a review of medical records from two communities
19. The quality of anticoagulation management
20. Studies on coumarin anticoagulant drugs: Initiation of warfarin therapy with a loading dose
21. Comparison of 5 mg and 10 mg loading doses in initiation of warfarin therapy
22. Aging and the anticoagulant response to warfarin therapy
23. The association of age with dosage requirement for warfarin
24. Factors affecting the maintenance dose of warfarin
25. Aging and warfarin therapy
26. Stereoselective disposition of warfarin in young and elderly subjects
27. Long-term anticoagulation therapy for atrial fibrillation in elderly patients: Efficacy, risk, and current patterns of use
28. Interindividual differences in the response to oral anticoagulants
29. Temporary discontinuation of warfarin therapy: Changes in the international normalized ratio
30. Evaluation of excessive anticoagulation in a group model health maintenance organization
31. 1
32. Anaphylactoid reactions and vitamin K
33. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation
34. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione
35. 1) compared with warfarin discontinuation
36. 1 in controlling excessive hypoprothrombinemia during anticoagulant therapy
37. 1 for correction of reduced prothrombin activity
38. 1
39. Low dose oral vitamin K reliably reverses over anticoagulation due to warfarin
40. Management of anticoagulation before and after elective surgery
41. Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin
42. Outpatient peri-operative and peri-procedure treatment with dalteparin for chronically anticoagulated patients at high risk for thromboembolic complications
43. Use of enoxaparin for the chronically anticoagulated patient before and after procedures
44. Dental surgery in anticoagulated patients
45. Hemostatic effect of tranexamic mouthwash in anticoagulant-treated patients undergoing oral surgery
46. Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: A prospective randomized study
47. Bleeding complications in oral anticoagulant therapy: An analysis of risk factors
48. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction: Second report of the Sixty Plus Reinfarction Study Research Group
49. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage
50. Management and prognosis of life-threatening bleeding during warfarin therapy
51. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
52. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1010 treatment years in 551 outpatients
53. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic
54. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT)
55. Bleeding and thromboembolism during anticoagulant therapy: A population based study in Rochester, Minnesota
56. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
57. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio
58. Management of oral anticoagulant therapy: Experience with an anticoagulation clinic
59. Complications of long-term anticoagulation
60. Anticoagulation clinics and the monitoring of anticoagulant therapy
61. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic
62. Age-related risks of long-term oral anticoagulant therapy
63. The performance of clinics for outpatient control of anticoagulation
64. Long-term oral anticoagulant therapy in elderly patients
65. Can old people on oral anticoagulants be safely managed as outpatients?
66. Age-associated risks of prophylactic anticoagulation in the setting of hip fracture
67. Management of anticoagulation in outpatients: Experience with an anticoagulation service in a municipal hospital setting
68. Hemorrhagic complications of anticoagulant therapy
69. Bleeding during antithrombotic therapy in patients with atrial fibrillation
70. The risk for and severity of bleeding complication in elderly patients treated with warfarin
71. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomized clinical trial
72. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage
73. Age related risks of long-term oral anticoagulant therapy
74. Low intensity anticoagulation in mechanical cardiac prosthetic valves
75. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation
76. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
77. Canadian atrial fibrillation anticoagulation (CAFA) study
78. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study
79. Therapeutic control of anticoagulant treatment
80. Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists
81. A method to determine the optimal intensity of oral anticoagulant therapy
82. Retrospective evaluation of a pharmacist-managed warfarin anticoagulation clinic
83. Anticoagulation in atrial fibrillation: Does efficacy in clinical trials translate into effectiveness in practice?
84. Identification and surveillance of patient on oral anticoagulant therapy in a large geographic area-use of laboratory information systems
85. Prevention of major bleeding in older patients treated with warfarin: Results of a randomized trial
86. Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy
87. A structured teaching and self-management program for patient receiving oral anticoagulation: A randomized controlled trial: Working group for the study of patient self-management of oral anticoagulation
88. Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis
89. Home prothrombin time monitoring after the initiation of warfarin therapy: A randomized, prospective study
90. Long-term patient self-management of oral anticoagulation
91. Nine-year experience with a pharmacist-managed anticoagulation clinic
92. An outpatient anticoagulation protocol managed by a vascular nurse-clinician
93. Stroke prevention in atrial fibrillation study: Final results
94. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study
95. Bleeding during warfarin and apirin therapy in patients treated with atrial fibrillation: The AFASAK 2 study
96. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke
97. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: Randomized controlled trial comparing two intensities of coumarin with aspirin
98. A model for planning optimal follow-up for outpatients on warfarin anticoagulation
99. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease
100. Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl
101. Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia
102. Protein C and the development of skin necrosis during anticoagulant therapy
103. Successful warfarin anticoagulant despite protein C deficiency and a history of warfarin necrosis
104. Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulation treatment
105. Necrosis of skin induced by coumarin in a patient deficient in protein S
106. Laboratory monitoring of oral anticoagulant therapy
107. Significance of occult gastrointestinal bleeding during anticoagulation therapy
108. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy
109. The significance of hematuria in the anticoagulated patient
110. Incidence and etiology of hematuria in patients on anticoagulant therapy
111. Clinical significance of hematuria in patients on anticoagulant therapy
112. Anticoagulant associated hematuria: A prospective study
113. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
114. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
115. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management
116. Anticoagulant control and the risk of bleeding
117. Thrombotic events during anticoagulant treatment: Results of the inception-cohort, prospective, collaborative ISCOAT study
118. Pharmacy operated anticoagulation service: Improved outcomes in patients on warfarin
119. Comparison of an anticoagulation clinic and usual medical care: Anticoagulation control, patient outcomes, and health care costs
120. The community impact of anticoagulation services: Rationale and design of the Managing Anticoagulation Services Trial (MAST)
121. Cost justification of a clinical pharmacist-managed anticoagulation clinic
122. Advances in the monitoring of oral anticoagulation: Point-of-care testing, patient self-monitoring, and patient self-management
123. A novel whole blood capillary technique for measuring prothrombin time
124. Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor
125. Evaluation of a capillary whole blood prothrombin time measurement system
126. Evaluation of the Cibra Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation
127. Accuracy and precision of a portable anticoagulation monitor in a clinical setting
128. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio?
129. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis
130. Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer
131. Pilot study to determine use of a TAS analyzer in an anticoagulation clinic setting
132. Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy
133. Accuracy of laboratory and portable monitor international normalized ratio determinations
134. Accurate and precise prothrombin time measurement in a multicenter anticoagulation trial employing patient self-testing
135. Monitoring of oral anticoagulant therapy in pediatric patients using a new microsample PT device
136. PT prothrombin time system
137. Point-of-care testing in coagulation and hemostasis: Implications for patient management
138. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy
139. Multicenter trial of accurate home self-testing in oral anticoagulant patients with a novel whole blood system
140. A self-control method for long-term anticoagulation therapy
141. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times
142. Experience with patient self-management of oral anticoagulation
143. Self-management of oral anticoagulant therapy after heart valve replacement
144. INR self-management following mechanical heart valve replacement: Are education level and therapeutic compliance connected?
145. Computer assisted management of warfarin treatment
146. Computer control of anticoagulant dose for therapeutic management
147. Computer control of anticoagulant dose
148. Prospective comparative study of computer programs used for management of warfarin
149. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy
150. The European Concerted Action on Anticoagulation (ECAA): Multicentre randomized study of computerized anticoagulant dosage
151. Maternal and fetal sequelae of anticoagulation during pregnancy
152. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves
153. Guidelines for prevention of thromboembolic events in valvular heart disease
154. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses
155. Safety of low molecular weight heparin in pregnancy: A systematic review
156. Prophylaxis of thromboembolism in pregnancy: An alternative
157. Is warfarin sodium contraindicated in the lactating mother?
158. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
159. The management of thrombosis in the antiphospholipid-antibody syndrome
160. Monitoring warfarin therapy in patients with lupus anticoagulants
161. Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants
162. Thrombosis in the antiphospholipid antibody syndrome
163. Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome
164. Thrombosis in the antiphospholipid antibody syndrome
165. The international normalized ratio (INR) for monitoring warfarin therapy: Reliability and relation to other monitoring methods
166. Plasma levels of factors II, VII, and X and their relationship to the international normalized ratio during chronic warfarin therapy
167. Comparison of native prothrombin antigen with prothrombin time for monitoring oral anticoagulant prophylaxis